This is the first case of advanced CRC with increased copy numbers of <i>KRAS</i> resistant to cetuximab and chemotherapy, which results in poor patient survival, and other mutated genes may be associated with the outcomes. This evidence concerns the gene KRAS and colorectal carcinoma.